RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary

RAMM Pharma Corp. announced a non-brokered private placement of up to 20,000,000 units at $0.05 per unit, aiming to raise $1,000,000 for working capital and corporate purposes.

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the “Units”) of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the “Offering”). Each Unit would have been comprised of one common share in the capital of the Company (each, a “Common Share”), and one Common Share purchase warrant (each a “Warrant”), with each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.05 for a perio d of 36 months following the closing date of the Offering. The proceeds from the Offering were expected to be used for working capital and general corporate purposes. The Offering was expected to close on or about September 26, 2023.

Ramm also announced its intention to commence a normal course issuer bid (the “NCIB”), under which it could have purchased up to 5% of the current number of issued and outstanding Common Shares. The NCIB would have commenced on or about September 5, 2023 and expired on the 12-month anniversary of the effective date of the NCIB.

Further reference to the proposed non-brokered private placement and the NCIB can be found on the Company’s announcement released on September 5th 2023.

On November 16, 2023, the Company received a decision from the CSE dismissing the appeal of its previous decision that the private placement announced by the Company on September 5, 2023 required shareholder approval pursuant to CSE Policy 4.6(2)(a)(iv).

The Company had reviewed the decision of the CSE Board with counsel and decided to appeal the decision to the Capital Markets Tribunal.

The appeal, which was scheduled for review on April 23^rd, has been withdrawn by the Company after consideration. The company is cancelling its previously proposed private placement and will advise the market at a later date should it decide to proceed with a future financing.

About RAMM Pharma Corp.
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company's state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay and Elblag, Poland.

In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.wearerammpharma.com.

For further information, please contact:

José Roldan Interim CFO
+598 2513 99 58
info@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “wi ll” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company’s strategies and objectives, and future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward -looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insu rance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward -looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward -looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. 

What did RAMM Pharma Corp. announce on September 5th, 2023?

RAMM Pharma Corp. announced its intention to complete a non-brokered private placement of up to 20,000,000 units at a price of $0.05 per unit.

How many units were included in the private placement?

The private placement included up to 20,000,000 units.

What was the price per unit in the private placement?

The price per unit in the private placement was $0.05.

What was the total gross proceeds expected from the private placement?

The total gross proceeds expected from the private placement were up to $1,000,000.

What were the proceeds from the private placement expected to be used for?

The proceeds from the private placement were expected to be used for working capital and general corporate purposes.